PMID- 27446535
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2049-9434 (Print)
IS  - 2049-9442 (Electronic)
IS  - 2049-9434 (Linking)
VI  - 5
IP  - 2
DP  - 2016 Aug
TI  - Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in 
      osteoporotic patients using proton pump inhibitors.
PG  - 165-170
AB  - It has been indicated that proton pump inhibitor (PPI) use is associated with a 
      loss of the anti-fracture efficacy of alendronate (AD). However, there are few 
      prospective studies that have investigated the efficacy of AD on lumbar bone 
      mineral density (BMD) in osteoporotic patients who are using PPIs. Thus, the aim 
      of the present study was to investigate the efficacy of alfacalcidol (AC) and AD 
      on lumbar BMD in osteoporotic patients using PPIs. A prospective, randomized, 
      active control study enrolled such osteoporotic patients (age, >/=50 years). The 
      patients were randomly assigned to receive AC (1 microg/day) or AD (35 mg/week) and 
      were followed up for one year. Patient profiles were maintained, and lumbar BMD, 
      bone-specific alkaline-phosphatase (BAP) and collagen type-I cross-linked 
      N-telopeptide (NTX), upper gastrointestinal endoscopy results, and the frequency 
      scale for the symptoms of gastroesophageal reflux disease (FSSG) were evaluated. 
      Percentage changes in lumbar BMD, NTX, BAP, and change in FSSG score from 
      baseline to the end of one year of treatment were investigated. Sixteen patients 
      were eligible for analysis (eight assigned to receive AC, eight assigned to 
      receive AD). The percentage change in lumbar BMD from baseline to the end of 
      treatment was -0.4+/-4.0% for the AC group vs. 6.8+/-6.3% for the AD group (P=0.015). 
      No significant percentage change of BAP and NTX between the two groups was 
      observed. Subsequent to one year of treatment, the FSSG score did not change from 
      the baseline values for either study group, and no new bone fractures or 
      esophagitis were observed in either group of patients. The findings demonstrated 
      that in osteoporotic patients using concomitant PPIs, there was a greater 
      increase in lumbar BMD after one year of treatment with AD compared with AC. 
      However, the number of study subjects was small; thus, further, large prospective 
      studies are required to determine the effect of AD in osteoporotic patients using 
      concomitant PPIs.
FAU - Asaoka, Daisuke
AU  - Asaoka D
AD  - Department of Gastroenterology, School of Medicine, University of Juntendo, Tokyo 
      113-8421, Japan.
FAU - Nagahara, Akihito
AU  - Nagahara A
AD  - Department of Gastroenterology, Juntendo University Shizuoka Hospital, Shizuoka 
      410-2295, Japan.
FAU - Hojo, Mariko
AU  - Hojo M
AD  - Department of Gastroenterology, School of Medicine, University of Juntendo, Tokyo 
      113-8421, Japan.
FAU - Matsumoto, Kenshi
AU  - Matsumoto K
AD  - Department of Gastroenterology, School of Medicine, University of Juntendo, Tokyo 
      113-8421, Japan.
FAU - Ueyama, Hiroya
AU  - Ueyama H
AD  - Department of Gastroenterology, School of Medicine, University of Juntendo, Tokyo 
      113-8421, Japan.
FAU - Matsumoto, Kohei
AU  - Matsumoto K
AD  - Department of Gastroenterology, School of Medicine, University of Juntendo, Tokyo 
      113-8421, Japan.
FAU - Izumi, Kentaro
AU  - Izumi K
AD  - Department of Gastroenterology, School of Medicine, University of Juntendo, Tokyo 
      113-8421, Japan.
FAU - Takeda, Tsutomu
AU  - Takeda T
AD  - Department of Gastroenterology, School of Medicine, University of Juntendo, Tokyo 
      113-8421, Japan.
FAU - Komori, Hiroyuki
AU  - Komori H
AD  - Department of Gastroenterology, School of Medicine, University of Juntendo, Tokyo 
      113-8421, Japan.
FAU - Akazawa, Yoichi
AU  - Akazawa Y
AD  - Department of Gastroenterology, School of Medicine, University of Juntendo, Tokyo 
      113-8421, Japan.
FAU - Shimada, Yuji
AU  - Shimada Y
AD  - Department of Gastroenterology, Juntendo University Shizuoka Hospital, Shizuoka 
      410-2295, Japan.
FAU - Osada, Taro
AU  - Osada T
AD  - Department of Gastroenterology, School of Medicine, University of Juntendo, Tokyo 
      113-8421, Japan.
FAU - Watanabe, Sumio
AU  - Watanabe S
AD  - Department of Gastroenterology, School of Medicine, University of Juntendo, Tokyo 
      113-8421, Japan.
LA  - eng
PT  - Journal Article
DEP - 20160630
PL  - England
TA  - Biomed Rep
JT  - Biomedical reports
JID - 101613227
PMC - PMC4950806
OTO - NOTNLM
OT  - alendronate
OT  - alfacalcidol
OT  - osteoporosis
OT  - prospective
OT  - proton pump inhibitor
OT  - randomized
EDAT- 2016/07/23 06:00
MHDA- 2016/07/23 06:01
PMCR- 2016/06/30
CRDT- 2016/07/23 06:00
PHST- 2016/04/14 00:00 [received]
PHST- 2016/06/24 00:00 [accepted]
PHST- 2016/07/23 06:00 [entrez]
PHST- 2016/07/23 06:00 [pubmed]
PHST- 2016/07/23 06:01 [medline]
PHST- 2016/06/30 00:00 [pmc-release]
AID - BR-0-0-710 [pii]
AID - 10.3892/br.2016.710 [doi]
PST - ppublish
SO  - Biomed Rep. 2016 Aug;5(2):165-170. doi: 10.3892/br.2016.710. Epub 2016 Jun 30.